Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation

Cancer Biology and Therapy

Volumn 6, Issue 8, 2007, Pages 1275-1281

  McCray, Andrea N ^a   Ugen, Kenneth E ^a   Heller, Richard ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

B16.F10 melanoma; Electrogenetherapy; HIV 1 Vpr; In vivo electroporation; Tumor regression

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; VIRUS DNA; VIRUS PROTEIN; VPR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG DOSE REGIMEN; ELECTROPORATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PLASMID; PROTEIN INDUCTION; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; GENE THERAPY; GENETICS; METHODOLOGY; SKIN TUMOR;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; ELECTROPORATION; GENE THERAPY; HIV-1; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLASMIDS; SKIN NEOPLASMS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 39749126905     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.8.4476     Document Type: Article

References (53)